Dow and Avidex Collaborate on Drug Discovery
By Biotechdaily staff writers
Posted on 15 Sep 2003
A collaboration to create biotargeted radiopharmaceuticals for the treatment of cancer has been announced by Avidex Limited (Milton Park, UK) and The Dow Chemical Company (Midland, MI, USA). Posted on 15 Sep 2003
The radiopharmaceuticals will be based on the monoclonal T-cell receptors (mTCRs) of Avidex. Chelation technology and other capabilities provided through the ChelaMed radiopharamceitucal services from Dow will be used to attach a therapeutic radioisotope to a targeted MTCR. Initial efforts will focus on Avidex's mTCR product, EsoDex, in order to enhance this targeted radiopharmaceutical for the treatment of lung and bladder cancer. EsoDex targets the NY-ESO antigen, a specific marker of cancer cells. Avidex is a spinoff of Oxford University (UK).
"Biotargeted radiopharmaceuticals can potentially increase therapeutic options, raise effectiveness, and reduce side effects to improve quality of life for patients with cancer and other diseases,” said Mark Cassidy, Ph.D., director, pharmaceutical technologies, at Dow.
Related Links:
Avidex
Dow Chemical